 | • レポートコード：MRC23Q36030 • 出版社/出版日：QYResearch / 2023年3月 • レポート形態：英文、PDF、90ページ • 納品方法：Eメール（2-3日） • 産業分類：医薬品 |
| Single User | ￥429,200 (USD2,900) | ▷ お問い合わせ |
| Enterprise License | ￥858,400 (USD5,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートは世界のジェネリック抗がん注射剤市場について調査・分析し、世界のジェネリック抗がん注射剤市場概要、市場トレンド、主要企業別競争状況、タイプ別セグメント分析（ベバシズマ、リツキシマブ、ハーセプチン、パクリタキセル、その他）、用途別セグメント分析（病院、小売）、地域別市場規模、主要企業のプロファイルなどに関する情報を掲載しています。主要企業としては、Teva、Viatris、Biocon、Amgen、Sandoz (Novartis)、Pfizer、Qilu Pharmaceutical、Jiangsu Hansoh、CTTQ、Jiangsu Hengrui、CSPC、Innovent Biologicsなどが含まれています。世界のジェネリック抗がん注射剤市場は、2022年にXXX米ドル、2029年にはXXX米ドルに達すると予測され、予測期間の年平均成長率はXXX％です。COVID-19とロシア・ウクライナ戦争の影響は、ジェネリック抗がん注射剤市場規模を推定する際に考慮しました。本レポートは、ジェネリック抗がん注射剤の世界市場を定量的・定性的な分析により包括的に提示し、読者がビジネス/成長戦略を策定し、市場競争状況を把握し、現在の市場における自社のポジションを分析し、ジェネリック抗がん注射剤に関するビジネス上の意思決定に役立てることを目的としています。 ・ジェネリック抗がん注射剤市場の概要 - ジェネリック抗がん注射剤のタイプ別セグメント - 世界のジェネリック抗がん注射剤市場規模：タイプ別分析（ベバシズマ、リツキシマブ、ハーセプチン、パクリタキセル、その他） - ジェネリック抗がん注射剤の用途別セグメント - 世界のジェネリック抗がん注射剤市場規模：用途別分析（病院、小売） - 世界のジェネリック抗がん注射剤市場規模予測（2018年-2029年） ・ジェネリック抗がん注射剤市場の成長トレンド - ジェネリック抗がん注射剤の地域別市場規模（2018年-2029年） - ジェネリック抗がん注射剤市場ダイナミクス - ジェネリック抗がん注射剤の業界動向 - ジェネリック抗がん注射剤市場の成長ドライバ、課題、阻害要因 ・主要企業別競争状況 - 企業別市場シェア - 世界の主要企業、業界ランキング分析 - 市場への参入、M＆A動向 ・タイプ別セグメント：ベバシズマ、リツキシマブ、ハーセプチン、パクリタキセル、その他 - 世界のジェネリック抗がん注射剤のタイプ別市場規模（2018年-2023年） - 世界のジェネリック抗がん注射剤のタイプ別市場規模（2024年-2029年） ・用途別セグメント：病院、小売 - 世界のジェネリック抗がん注射剤の用途別市場規模（2018年-2023年） - 世界のジェネリック抗がん注射剤の用途別市場規模（2024年-2029年） ・ジェネリック抗がん注射剤の地域別市場規模 - 北米のジェネリック抗がん注射剤市場規模（2018年-2029年） - アメリカのジェネリック抗がん注射剤市場規模（2018年-2029年） - ヨーロッパのジェネリック抗がん注射剤市場規模（2018年-2029年） - アジア太平洋のジェネリック抗がん注射剤市場規模（2018年-2029年） - 中国のジェネリック抗がん注射剤市場規模（2018年-2029年） - 日本のジェネリック抗がん注射剤市場規模（2018年-2029年） - 韓国のジェネリック抗がん注射剤市場規模（2018年-2029年） - インドのジェネリック抗がん注射剤市場規模（2018年-2029年） - オーストラリアのジェネリック抗がん注射剤市場規模（2018年-2029年） - 中南米のジェネリック抗がん注射剤市場規模（2018年-2029年） - 中東・アフリカのジェネリック抗がん注射剤市場規模（2018年-2029年） ・主要企業のプロファイル：企業情報、事業概要、売上、動向 Teva、Viatris、Biocon、Amgen、Sandoz (Novartis)、Pfizer、Qilu Pharmaceutical、Jiangsu Hansoh、CTTQ、Jiangsu Hengrui、CSPC、Innovent Biologics ・アナリストの観点/結論 ・調査方法とデータソース |
Highlights
The global Generic Anti-cancer Injectables market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Generic Anti-cancer Injectables is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Generic Anti-cancer Injectables is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for Generic Anti-cancer Injectables in Hospital is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of Generic Anti-cancer Injectables include Teva, Viatris, Biocon, Amgen, Sandoz (Novartis), Pfizer, Qilu Pharmaceutical, Jiangsu Hansoh and CTTQ, etc. In 2022, the world’s top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Generic Anti-cancer Injectables, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Generic Anti-cancer Injectables.
The Generic Anti-cancer Injectables market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Generic Anti-cancer Injectables market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Generic Anti-cancer Injectables companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Teva
Viatris
Biocon
Amgen
Sandoz (Novartis)
Pfizer
Qilu Pharmaceutical
Jiangsu Hansoh
CTTQ
Jiangsu Hengrui
CSPC
Innovent Biologics
Segment by Type
Bevacizuma
Rituximab
Herceptin
Paclitaxel
Others
Segment by Application
Hospital
Retail
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Generic Anti-cancer Injectables companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Generic Anti-cancer Injectables Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Bevacizuma
1.2.3 Rituximab
1.2.4 Herceptin
1.2.5 Paclitaxel
1.2.6 Others
1.3 Market by Application
1.3.1 Global Generic Anti-cancer Injectables Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospital
1.3.3 Retail
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Generic Anti-cancer Injectables Market Perspective (2018-2029)
2.2 Generic Anti-cancer Injectables Growth Trends by Region
2.2.1 Global Generic Anti-cancer Injectables Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Generic Anti-cancer Injectables Historic Market Size by Region (2018-2023)
2.2.3 Generic Anti-cancer Injectables Forecasted Market Size by Region (2024-2029)
2.3 Generic Anti-cancer Injectables Market Dynamics
2.3.1 Generic Anti-cancer Injectables Industry Trends
2.3.2 Generic Anti-cancer Injectables Market Drivers
2.3.3 Generic Anti-cancer Injectables Market Challenges
2.3.4 Generic Anti-cancer Injectables Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Generic Anti-cancer Injectables Players by Revenue
3.1.1 Global Top Generic Anti-cancer Injectables Players by Revenue (2018-2023)
3.1.2 Global Generic Anti-cancer Injectables Revenue Market Share by Players (2018-2023)
3.2 Global Generic Anti-cancer Injectables Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Generic Anti-cancer Injectables Revenue
3.4 Global Generic Anti-cancer Injectables Market Concentration Ratio
3.4.1 Global Generic Anti-cancer Injectables Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Generic Anti-cancer Injectables Revenue in 2022
3.5 Generic Anti-cancer Injectables Key Players Head office and Area Served
3.6 Key Players Generic Anti-cancer Injectables Product Solution and Service
3.7 Date of Enter into Generic Anti-cancer Injectables Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Generic Anti-cancer Injectables Breakdown Data by Type
4.1 Global Generic Anti-cancer Injectables Historic Market Size by Type (2018-2023)
4.2 Global Generic Anti-cancer Injectables Forecasted Market Size by Type (2024-2029)
5 Generic Anti-cancer Injectables Breakdown Data by Application
5.1 Global Generic Anti-cancer Injectables Historic Market Size by Application (2018-2023)
5.2 Global Generic Anti-cancer Injectables Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Generic Anti-cancer Injectables Market Size (2018-2029)
6.2 North America Generic Anti-cancer Injectables Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Generic Anti-cancer Injectables Market Size by Country (2018-2023)
6.4 North America Generic Anti-cancer Injectables Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Generic Anti-cancer Injectables Market Size (2018-2029)
7.2 Europe Generic Anti-cancer Injectables Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Generic Anti-cancer Injectables Market Size by Country (2018-2023)
7.4 Europe Generic Anti-cancer Injectables Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Generic Anti-cancer Injectables Market Size (2018-2029)
8.2 Asia-Pacific Generic Anti-cancer Injectables Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Generic Anti-cancer Injectables Market Size by Region (2018-2023)
8.4 Asia-Pacific Generic Anti-cancer Injectables Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Generic Anti-cancer Injectables Market Size (2018-2029)
9.2 Latin America Generic Anti-cancer Injectables Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Generic Anti-cancer Injectables Market Size by Country (2018-2023)
9.4 Latin America Generic Anti-cancer Injectables Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Generic Anti-cancer Injectables Market Size (2018-2029)
10.2 Middle East & Africa Generic Anti-cancer Injectables Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Generic Anti-cancer Injectables Market Size by Country (2018-2023)
10.4 Middle East & Africa Generic Anti-cancer Injectables Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Teva
11.1.1 Teva Company Detail
11.1.2 Teva Business Overview
11.1.3 Teva Generic Anti-cancer Injectables Introduction
11.1.4 Teva Revenue in Generic Anti-cancer Injectables Business (2018-2023)
11.1.5 Teva Recent Development
11.2 Viatris
11.2.1 Viatris Company Detail
11.2.2 Viatris Business Overview
11.2.3 Viatris Generic Anti-cancer Injectables Introduction
11.2.4 Viatris Revenue in Generic Anti-cancer Injectables Business (2018-2023)
11.2.5 Viatris Recent Development
11.3 Biocon
11.3.1 Biocon Company Detail
11.3.2 Biocon Business Overview
11.3.3 Biocon Generic Anti-cancer Injectables Introduction
11.3.4 Biocon Revenue in Generic Anti-cancer Injectables Business (2018-2023)
11.3.5 Biocon Recent Development
11.4 Amgen
11.4.1 Amgen Company Detail
11.4.2 Amgen Business Overview
11.4.3 Amgen Generic Anti-cancer Injectables Introduction
11.4.4 Amgen Revenue in Generic Anti-cancer Injectables Business (2018-2023)
11.4.5 Amgen Recent Development
11.5 Sandoz (Novartis)
11.5.1 Sandoz (Novartis) Company Detail
11.5.2 Sandoz (Novartis) Business Overview
11.5.3 Sandoz (Novartis) Generic Anti-cancer Injectables Introduction
11.5.4 Sandoz (Novartis) Revenue in Generic Anti-cancer Injectables Business (2018-2023)
11.5.5 Sandoz (Novartis) Recent Development
11.6 Pfizer
11.6.1 Pfizer Company Detail
11.6.2 Pfizer Business Overview
11.6.3 Pfizer Generic Anti-cancer Injectables Introduction
11.6.4 Pfizer Revenue in Generic Anti-cancer Injectables Business (2018-2023)
11.6.5 Pfizer Recent Development
11.7 Qilu Pharmaceutical
11.7.1 Qilu Pharmaceutical Company Detail
11.7.2 Qilu Pharmaceutical Business Overview
11.7.3 Qilu Pharmaceutical Generic Anti-cancer Injectables Introduction
11.7.4 Qilu Pharmaceutical Revenue in Generic Anti-cancer Injectables Business (2018-2023)
11.7.5 Qilu Pharmaceutical Recent Development
11.8 Jiangsu Hansoh
11.8.1 Jiangsu Hansoh Company Detail
11.8.2 Jiangsu Hansoh Business Overview
11.8.3 Jiangsu Hansoh Generic Anti-cancer Injectables Introduction
11.8.4 Jiangsu Hansoh Revenue in Generic Anti-cancer Injectables Business (2018-2023)
11.8.5 Jiangsu Hansoh Recent Development
11.9 CTTQ
11.9.1 CTTQ Company Detail
11.9.2 CTTQ Business Overview
11.9.3 CTTQ Generic Anti-cancer Injectables Introduction
11.9.4 CTTQ Revenue in Generic Anti-cancer Injectables Business (2018-2023)
11.9.5 CTTQ Recent Development
11.10 Jiangsu Hengrui
11.10.1 Jiangsu Hengrui Company Detail
11.10.2 Jiangsu Hengrui Business Overview
11.10.3 Jiangsu Hengrui Generic Anti-cancer Injectables Introduction
11.10.4 Jiangsu Hengrui Revenue in Generic Anti-cancer Injectables Business (2018-2023)
11.10.5 Jiangsu Hengrui Recent Development
11.11 CSPC
11.11.1 CSPC Company Detail
11.11.2 CSPC Business Overview
11.11.3 CSPC Generic Anti-cancer Injectables Introduction
11.11.4 CSPC Revenue in Generic Anti-cancer Injectables Business (2018-2023)
11.11.5 CSPC Recent Development
11.12 Innovent Biologics
11.12.1 Innovent Biologics Company Detail
11.12.2 Innovent Biologics Business Overview
11.12.3 Innovent Biologics Generic Anti-cancer Injectables Introduction
11.12.4 Innovent Biologics Revenue in Generic Anti-cancer Injectables Business (2018-2023)
11.12.5 Innovent Biologics Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details